electroCore Files FDA 510(k) to Expand Quell Into Chemo-Induced Nerve Pain
ECOR sits 73% above its 52-week low of $4.41.
Summary
electroCore submitted a 510(k) to the FDA seeking clearance of its Quell wearable for chronic chemotherapy-induced peripheral neuropathy (CIPN), backed by two studies totaling 168 patients. The data showed roughly 40% pain reduction versus 24-33% for sham, and a quality-of-life improvement of 11.6% versus 8.7% on the EORTC-CIPN20 scale that met the pre-set significance threshold in the randomized trial. No FDA-cleared therapy currently carries a CIPN-specific indication, so a clearance would give Quell a first-mover label in oncology supportive care and could support reimbursement and pricing. This is an early regulatory step, not an approval: the FDA may request more data, and timing and final indication scope are uncertain. The company remains under a going-concern warning from its last 10-Q, which raises the stakes on any label expansion that could broaden the commercial market.
At the time of this announcement, ECOR was trading at $7.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70M. The 52-week trading range was $4.41 to $12.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.